---
title: "Why Did Azitra (AZTR) Stock Jump Over 25% After Hours?"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/290277251.md"
description: "Azitra (AZTR) shares surged 25.45% after hours to $0.22, reversing an intraday decline. The jump followed a shareholder letter detailing a $10.5 million financing round and expansion into cosmetic ingredients. Additionally, the company announced that its COO will present pipeline updates at the upcoming BIO International Convention."
datetime: "2026-06-19T07:06:00.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/290277251.md)
  - [en](https://longbridge.com/en/news/290277251.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/290277251.md)
generator: "portal-rs"
---

# Why Did Azitra (AZTR) Stock Jump Over 25% After Hours?

**Azitra Inc.** (NYSE:AZTR) shares soared 25.45% to $0.22 after the bell on Thursday.

The surge in the stock of the Connecticut-based biopharmaceutical company in the late trading session follows an intraday decline of 15.42%, closing the regular session at $0.17, according to Benzinga Pro data. 

Volume on Thursday surged to 120.22 million shares, approximately 9.1 times the stock’s average daily volume of 13.21 million shares, indicating exceptionally strong trading activity.

## Pipeline Diversification

On Wednesday, CEO **Francisco Salva** issued a letter to shareholders outlining new growth initiatives, pointing to a $10.5 million financing round completed in March as the catalyst, with up to $21 million more available through warrant exercises. 

The capital is funding expansion into **ATR-COSF**, a recombinant filaggrin protein for the cosmetic ingredient market targeting fine lines and wrinkles.

Azitra’s Cofounder and Chief Operating Officer, **Travis Whitfill** will present at the BIO International Convention, being held Jun. 22-25, according to a Tuesday announcement. The presentation will highlight recent updates and progress in Azitra’s pipeline, and Dr. Whitfill will conduct one-on-one meetings with registered investors and potential partners, showcasing the company’s business and clinical development strategy, recent corporate achievements and anticipated milestones.

## Trading Metrics, Technical Analysis

Azitra has a market capitalization of $2.82 million. The stock has traded between a 52-week high of $1.83 and a 52-week low of $0.10.

The stock has a Relative Strength Index (RSI) of 38.17.

Over the past 12 months, AZTR has dropped 89.53%.

The small-cap stock is currently trading close to its annual low.

**Price Action:** According to Benzinga Pro data, AZTR closed the regular session at $0.17, down 15.42%.

**Benzinga’s Edge Stock Rankings** indicate that AZTR is experiencing long-term consolidation along with medium and short-term upward movement.

*Photo Courtesy: prassarp on Shutterstock.com*

**Disclaimer:** This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.

 **Read Also: Qnity Electronics Stock Trends After Hours: CEO Tells Jim Cramer Company 'Right At The Center' Of Materials Innovation, The 'Hidden Hero' Of AI Era**

### Related Stocks

- [AZTR.US](https://longbridge.com/en/quote/AZTR.US.md)
- [Q.US](https://longbridge.com/en/quote/Q.US.md)
- [SSTK.US](https://longbridge.com/en/quote/SSTK.US.md)
- [Q*.US](https://longbridge.com/en/quote/Q*.US.md)

## Related News & Research

- [Azitra says shareholder letter is available](https://longbridge.com/en/news/290049526.md)
- [Azitra CEO outlines strategic reorientation, $10.5M financing, ATR-COSF and recombinant protein initiatives](https://longbridge.com/en/news/290051019.md)
- [Nutra Pharma files Form 3 as Pure Raw Supplies reports 12 million Series B preferred shares](https://longbridge.com/en/news/297690871.md)
- [$100 Invested In Darling Ingredients 10 Years Ago Would Be Worth This Much Today](https://longbridge.com/en/news/297667597.md)
- [OpenAI says upcoming model is so capable it requires stronger guardrails](https://longbridge.com/en/news/297691395.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**